Is Dalargin FDA approved?

Dalargin is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

Is Desmopressin FDA approved?

Desmopressin is FDA approved (FDA status current as of 1978-01-01). This regulatory status is provided for research and educational context only.

How is Dalargin administered in research settings?

In research settings, Dalargin is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is Desmopressin administered in research settings?

In research settings, Desmopressin is typically administered via the intranasal, oral, or subcutaneous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Dalargin vs Desmopressin

Peptide Comparison

Dalargin vs Desmopressin

Q: What is the difference between Dalargin and Desmopressin?

Dalargin: Binds delta and mu opioid receptors with peripheral preference due to limited CNS penetration. Desmopressin: Synthetic vasopressin analogue (V2R selective); crosses blood-brain barrier; enhances hippocampal LTP and memory consolidation; longer-acting than natural vasopressin

Both are Neuro & Cognitive peptides.

Dalargin

Leu-enkephalin-Arg

RecoveryNot EvaluatedResearch Only

No providers listed yet

Full Dalargin profile →

Desmopressin

DDAVP

CognitiveFDA ApprovedPrescription

Half-life: 1.5-2.5 hours (intranasal)

2 providers listed

Full Desmopressin profile →

Bottom line

Desmopressin is FDA-approved, while Dalargin is not evaluated — the clearest structural difference between them.

Quick Verdict

Dalargin

Evidence

Preclinical

Half-life

—

Desmopressin

Evidence

Clinical

Half-life

1.5-2.5 hours (intranasal)

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Desmopressin
Further along in FDA review	Desmopressin
Oral administration option	Desmopressin
More provider options (0 vs 2)	Desmopressin

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Dalargin

Desmopressin

Mechanism Family

Neuro & Cognitive

Half-life

—

1.5-2.5 hours (intranasal)

FDA Status

not evaluated

approved

Admin Routes

subcutaneous, intravenous

intranasal, oral, subcutaneous

Availability

Research Only

Prescription

Providers

None listed

2 listed

FDA Update

—

Jan 1978

Avail. Notes

—

FDA-approved synthetic vasopressin analog. Brands: DDAVP (NDA 017922), Stimate, Nocdurna (NDA 201532, Jun 2018). Approved forms: injection, intranasal, oral, sublingual. Prescription only.

Research Evidence

Dalargin

PreclinicalAnimal · 1 key study · dated evidence base — most recent 2009

Desmopressin

ClinicalRCT · 7 key studies · most recent 2026

Research Citations

Dalargin

Animal2009 · Bulletin of Experimental Biology and Medicine

Gastroprotective effect of dalargin in gastropathy due to treatment with nonsteroid antiinflammatory drugs

Desmopressin

Cohort2026 · BMC Nephrol

Proactive desmopressin for the prevention of serum sodium overcorrection in moderate-to-severe hyponatremia:…

Cohort2026 · Clinical Endocrinology

Clinical Outcomes Following Supply-Driven Transition From Intranasal to Oral Desmopressin in AVP-Deficiency

Cohort2026 · Int J Urol

Nationwide Trends in Desmopressin Prescribing for Nocturnal Polyuria in Japan: A Population-Based Analysis (2…

Cohort2026 · J Pediatr Hematol Oncol

Bleeding Phenotypes in Inherited Platelet Function Disorders: Insights From the ATHNdataset.

+3 more

About Dalargin

Binds delta and mu opioid receptors with peripheral preference due to limited CNS penetration. Reduces gastric acid secretion, promotes mucosal blood flow, and inhibits ulcer formation via prostaglandin-mediated pathways.

Research Areas

gastroprotectionGI repairanti-ulcerpain modulation

About Desmopressin

Synthetic vasopressin analogue (V2R selective); crosses blood-brain barrier; enhances hippocampal LTP and memory consolidation; longer-acting than natural vasopressin

Research Areas

memory consolidationlearning enhancementantidiuretichemostasis

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Dalargin

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Desmopressin

Reported (Unverified — Pending Clinical Review)

hyponatremiaheart failureuncontrolled hypertensionpsychogenic polydipsia

No established clinical contraindications

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Find Providers

Where to source these peptides

Providers offering

Dalargin

Browse directory →

Providers offering

Desmopressin

2 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Neuro & Cognitive Comparisons

Browse all peptides →

Educational research tools — not medical advice.